Company: INMB
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001213900-25-041072
Chunk: 5

Company: Inmune Bio, Inc.
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 1
Chunk 5
---
 key driver of innate immune dysfunction and mechanistic target of
many diseases. DN-TNF is currently being developed for Alzheimer’s and treatment resistant depression (“XPro”). The CORDStrom product platform is a pooled, human umbilical cord mesenchymal stem
cell product currently being developed to treat recessive dystrophic epidermolysis bullosa (“RDEB”). The Natural Killer Cell
Priming Platform includes INKmune aimed at priming the patient’s NK cells to eliminate minimal residual disease in patients with
cancer. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic
malignancies, solid tumors and chronic inflammation.

NOTE 2 – GOING CONCERN

These unaudited condensed consolidated financial
statements have been prepared in accordance with generally accepted accounting principles applicable to a going concern, which contemplates
the realization of assets and the satisfaction of liabilities in the normal course of business.

 The Company has incurred significant losses and
negative cash flows from operations since inception and expects to incur additional losses until such time that it can generate significant
revenue from the commercialization of its product candidates. During the three months ended March 31, 2025, the Company incurred a net
loss of $9.7 million and had net cash flows used in operating activities of $6.8 million. Given the Company’s projected
operating requirements and its existing cash and cash equivalents, the Company is projecting insufficient liquidity to sustain its operations
through one year following the date that the financial statements are issued. These conditions and events raise substantial doubt about
the Company’s ability to continue as a going concern.

In response to these conditions, management is
currently evaluating different strategies to obtain the required funding of future operations. Financing strategies may include, but are
not limited to, the public or private sale of equity, debt financings or funds from other capital sources, such as government funding,
collaborations, strategic alliances, divestment of non-core assets, or licensing arrangements with third parties. There can be no assurances
that the Company will be able to secure additional financing, or if available, that it will be sufficient to meet its needs or on favorable
terms. Because management’s plans have not yet been finalized and are not within the Company’s control, the implementation
of such plans cannot be considered probable. As a result, the Company has concluded that management’s plans do not alleviate substantial
doubt about